Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis
Open Access
Abstract
Objective: Platelet-to-lymphocyte ratio (PLR), known as a key systemic inflammatory parameter, has been proved to be associated with response to neoadjuvant therapy in breast cancer (BC); however, the results remain controversial. This meta-analysis was carried out to evaluate the prognostic values of PLR in patients with BC treated with neoadjuvant chemotherapy (NACT). Design: Meta-analysis. Data sources: Relevant literature published on the following databases: PubMed, Embase, Web of Science databases and the Cochrane Library. Eligibility criteria: All studies involving patients with BC treated with NACT and peripheral blood pretreatment PLR recorded were included. Data extraction and synthesis: Two researchers independently extracted and evaluated HR/OR and its 95% CI of survival outcomes, pathological complete response (pCR) rate and clinicopathological parameters. Results: The last search was updated to 31 December 2022. A total of 22 studies with 5533 patients with BC treated with NACT were enrolled in the final meta-analysis. Our results demonstrate that elevated PLR value appears to correlate with low pCR rate (HR 0.77, 95% CI 0.67 to 0.88, p2 =75.80%, P h 2 =7.40%, P h =0.365) and disease-free survival (HR 1.97, 95% CI 1.56 to 2.50, p2 =0.0%, P h =0.460). Furthermore, PLR level was associated with age (OR 0.86, 95% CI 0.79 to 0.93, p2 =40.60%, P h =0.096), menopausal status (OR 0.83, 95% CI 0.76 to 0.90, p2 =50.80%, P h =0.087) and T stage (OR 1.05, 95% CI 1.00 to 1.11, p=0.035; I 2 =70.30%, P h =0.005) of patients with BC. Conclusions: This meta-analysis demonstrated that high PLR was significantly related to the low pCR rate, poor OS and disease-free survival (DFS) of patients with BC treated with NACT. Therefore, PLR can be used as a potential predictor biomarker for the efficacy of NACT in BC.Keywords
Funding Information
- Natural Science Foundation of Jiangsu Province (BK20191208)
- Talent Program Foundation of Health and Family Planning Commission of Nantong (MA202009)
This publication has 80 references indexed in Scilit:
- Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast CancerClinical Cancer Research, 2013
- Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 womenBMJ, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer CellsPLOS ONE, 2011
- Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinomaBritish Journal of Cancer, 2006
- The Immunobiology of Cancer Immunosurveillance and ImmunoeditingImmunity, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Review: Role of Blood Platelets in Infection and InflammationJournal of Interferon & Cytokine Research, 2002
- Preoperative (neoadjuvant) chemotherapy in patients with breast cancerSeminars in Oncology, 2001
- Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancerCancer, 1983